Exendin-4

Supplier: SAFE AND SURE NEDERLAND B.V.

PRT111-0001 PRT111-0500
76003-322EA 240.89 USD
76003-322 76003-324
Exendin-4
Proteins and Peptides

GLP-1 receptor agonist


His-Gly-Glu-Gly-Thr-Phe-T​hr-Ser-Asp-Leu-Ser-Lys-Gl​n-Met-Glu-Glu-Glu-Ala-Val​-Arg-Leu-Phe-Ile-Glu-Trp-​Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pr​o-Ser-NH2

Exendin-4 is a 39 aa polypeptide and incretin mimetic which was first isolated from Gila monster saliva. The synthetic form, Exenatide, is a glucagon like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II. Research shows Exendin-4 is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain.


Exendin-4 is a 39 aa polypeptide and incretin mimetic which was first isolated from Gila monster saliva. The synthetic form, Exenatide, is a glucagon like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II. Research shows Exendin-4 is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain.


His-Gly-Glu-Gly-Thr-Phe-T​hr-Ser-Asp-Leu-Ser-Lys-Gl​n-Met-Glu-Glu-Glu-Ala-Val​-Arg-Leu-Phe-Ile-Glu-Trp-​Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pr​o-Ser-NH2

Exendin-4 is a 39 aa polypeptide and incretin mimetic which was first isolated from Gila monster saliva. The synthetic form, Exenatide, is a glucagon like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II. Research shows Exendin-4 is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR